Entera Bio (NASDAQ:ENTX) Cut to "Strong Sell" at Wall Street Zen

Key Points

• Wall Street Zen downgraded Entera Bio to “strong sell” from “sell.” However, broader analyst sentiment remains “Moderate Buy,” with an average price target of $9.60.
• Entera Bio reported a quarterly loss of $0.11 per share, missing analysts’ estimate of a $0.06 loss; analysts expect a full-year loss of $0.40 per share.
• Shares opened at $3.14 and were up 5.0% in the session described. The stock’s 12-month range is $0.91 to $4.20.

Entera Bio (NASDAQ:ENTX - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "sell" rating to a "strong sell" rating in a report released on Saturday, Wall Street Zen reports.

ENTX has been the subject of several other reports. UBS Group set a $9.00 price objective on shares of Entera Bio in a report on Friday, September 18th. Cantor Fitzgerald began coverage on Entera Bio in a research note on Tuesday, September 22nd. They issued an "overweight" rating on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Entera Bio in a research report on Thursday, October 15th. Guggenheim initiated coverage on shares of Entera Bio in a research note on Thursday, September 24th. They issued a "buy" rating and a $11.00 price target on the stock. Finally, Leerink Partners assumed coverage on shares of Entera Bio in a report on Friday, September 18th. They issued an "outperform" rating and a $9.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $9.60.

Entera Bio Trading Up 5.0%

Shares of Entera Bio stock opened at $3.14 on Friday. The company has a market capitalization of $546.11 million, a PE ratio of -8.97 and a beta of 1.48. Entera Bio has a 12 month low of $0.91 and a 12 month high of $4.20. The stock's fifty day simple moving average is $2.88 and its 200 day simple moving average is $1.95.

Entera Bio (NASDAQ:ENTX - Get Free Report) last issued its quarterly earnings results on Friday, November 6th. The company reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.05). Analysts predict that Entera Bio will post -0.40 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Entera Bio stock. Seven Fleet Capital Management LP raised its position in shares of Entera Bio Ltd. (NASDAQ:ENTX - Free Report) by 51.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 205,542 shares of the company's stock after acquiring an additional 70,224 shares during the quarter. Seven Fleet Capital Management LP owned about 0.42% of Entera Bio worth $228,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 14.11% of the company's stock.

Entera Bio Company Profile

Entera Bio Ltd. is a clinical-stage biotechnology company developing orally administered therapies based on its proprietary platform for delivering large-molecule drugs, including peptides and proteins. The company's technology is designed to address the challenges that typically limit the oral delivery of biologic medicines.

Entera Bio's lead program is EB613, an oral tablet formulation of parathyroid hormone (PTH 1-34) being developed for the treatment of postmenopausal osteoporosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.